A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer (Q39903605)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
scientific article

    Statements

    A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit